Please assess the completion status of the following clinical trial:

Trial Title: Docohexanoic Acid in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 years~* chronic stabilized HD treatment for at least 3 months with functional vascular access (arteriovenous fistula or permanent catheter)~* equilibrated Kt/V urea (eKt/V)higher than 1.2~* informed consent form signed~Exclusion Criteria:~* exposure to corticosteroids and anti-inflammatory drugs or hospital admissions in last 3 months~* were with ongoing active illnesses, wasting, connective tissue disease, metastatic cancer or malignancy, HIV, uncontrolled chronic hepatic disease or transplantation prior to the start of the study.~* Patients with known hypersensitivity to any of fish intolerance or allergy, history of gastrointestinal bleeding, patients already receiving chronic anticoagulation therapy (antiplatelet agents or warfarin), and patients with terminal or life-threatening disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): The patients on this arm received usual medical care
- DHA supplementation (Type: ACTIVE_COMPARATOR): The patients on this arm received DHA supplementation (650 mg DHA/3 times/wk/post-HD session)

Based on this trial design, predict the completion outcome and termination type (if applicable).